Journal
SCIENTIFIC REPORTS
Volume 10, Issue 1, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41598-020-71877-z
Keywords
-
Categories
Funding
- Inserm [U1036]
- CEA (DRF/IRIG/DS/BCI)
- UGA
- National Institute for Research on Agronomy and Environment (INRAE)
- Regional Council of Burgundy France
- FEDER (European Funding for Regional Economical Development)
- Association Nationale Recherche Technologie
- Fondation de France/Fondation de l'Oeil
- Fondation pour la Recherche Medicale (FRM)
- Fondation ARC pour la Recherche sur le Cancer
- Association Maladie de Rendu-Osler (AMRO/HHT-France)
- Ligue Departementale contre le Cancer de l'Isere et de la Savoie
- Agence Nationale de la Recherche (ANR) [ANR-17-CE14-0006]
- Labex GRAL [ANR-10-LABX-49-01]
Ask authors/readers for more resources
Aqueous humor drainage is essential for the regulation of intraocular pressure (IOP), a major risk factor for glaucoma. The Schlemm's canal and the non-conventional uveoscleral pathway are known to drain aqueous humor from the eye anterior chamber. It has recently been reported that lymphatic vessels are involved in this process, and that the Schlemm's canal responds to some lymphatic regulators. We have previously shown a critical role for bone morphogenetic protein 9 (BMP9) in lymphatic vessel maturation and valve formation, with repercussions in drainage efficiency. Here, we imaged eye lymphatic vessels and analyzed the consequences of Bmp9 (Gdf2) gene invalidation. A network of lymphatic vessel hyaluronan receptor 1 (LYVE-1)-positive lymphatic vessels was observed in the corneolimbus and the conjunctiva. In contrast, LYVE-1-positive cells present in the ciliary bodies were belonging to the macrophage lineage. Although enlarged conjunctival lymphatic trunks and a reduced valve number were observed in Bmp9-KO mice, there were no morphological differences in the Schlemm's canal compared to wild type animals. Moreover, there were no functional consequences on IOP in both basal control conditions and after laser-induced ocular hypertonia. Thus, the BMP9-activated signaling pathway does not constitute a wise target for new glaucoma therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available